Core Viewpoint - Allurion Technologies is experiencing a rise in share price following the announcement of a planned clinical study to evaluate the combination of its Allurion Program with GLP-1 agonists [1] Group 1: Clinical Study and Weight Loss - The company is addressing concerns regarding muscle loss associated with GLP-1 treatments, which can lead to a reduction of approximately 40% in lean mass relative to total weight lost [2] - Allurion's previous studies indicate that its gastric balloon, along with the Virtual Care Suite, has enabled patients to lose weight while maintaining or even increasing muscle mass [2] - The planned study aims to confirm if the combination of the Allurion Balloon and Virtual Care Suite with GLP-1 therapy can provide a more metabolically healthy approach to weight loss, potentially positioning the Allurion Program as a leading option in obesity treatment [3] Group 2: Financial Developments - The company has entered into a securities purchase agreement to raise approximately $7.4 million in gross proceeds through the sale of 1.24 million shares at $6.00 per share [4] - Roth Capital Partners is acting as the exclusive placement agent for this offering, which is expected to close on or around January 27, 2025, pending customary closing conditions [5] - The net proceeds from the offering are intended for working capital and general corporate purposes [5] Group 3: Market Reaction - Allurion shares increased by 120% to $8.15 at the time of publication, reflecting positive market sentiment following the announcements [5]

Core Insights - Allurion Technologies (ALUR) shares tripled as the company aims to leverage the growing obesity drug market by testing its gastric balloon in combination with GLP-1 medications [1][4] - Previous research indicated that GLP-1 treatments resulted in approximately 40% reduction in lean mass as a proportion of total weight lost, while Allurion's gastric balloon users maintained or even increased muscle mass [2][4] - The CEO highlighted the significance of muscle mass decline in GLP-1 users and suggested that the combination of the gastric balloon and GLP-1 could set a new standard in obesity care [3] Company Developments - Allurion Technologies announced plans to conduct a study to evaluate the effectiveness of its gastric balloon alongside popular GLP-1 drugs [1][4] - The company has faced a challenging year, with shares down over 85% from their peak in summer 2023, despite the recent surge [3][4] Market Context - The obesity drug market is experiencing significant growth, prompting Allurion to explore innovative solutions to enhance weight loss outcomes while preserving muscle mass [1][3]

Financial Performance - Allurion generated revenue of $26.5 million for the nine months ended September 30, 2024, a decrease of 41.5% compared to $45.2 million for the same period in 2023[149] - The company incurred a net loss of $5.6 million for the nine months ended September 30, 2024, significantly reduced from a net loss of $61.4 million for the same period in 2023[149] - Revenue decreased by $12.8 million, or 71%, to $5.4 million for the three months ended September 30, 2024, and decreased by $18.7 million, or 41%, to $26.5 million for the nine months ended September 30, 2024, compared to the same periods in 2023[171] - The net loss for the three months ended September 30, 2024, was $9.0 million, compared to a net loss of $21.6 million for the same period in 2023, reflecting a decrease of $12.6 million[170] - The loss from operations was $12.3 million for the three months ended September 30, 2024, compared to a loss of $26.2 million for the same period in 2023, indicating an improvement of $13.8 million[170] - The company incurred a net loss of $61.4 million for the nine months ended September 30, 2023, compared to a net loss of $5.6 million for the same period in 2024[182] Cash Flow and Financing - Cash outflows from operating activities were $29.0 million for the nine months ended September 30, 2024, down from $43.1 million in the same period in 2023[182] - Cash provided by financing activities was $20.3 million for the nine months ended September 30, 2024, compared to $116.4 million in the same period of 2023[195][197] - The company received $15.2 million in net proceeds from the issuance of common stock and warrants on July 1, 2024[185] - The Company issued $48 million in convertible senior secured notes with a 6.0% annual interest rate, maturing on April 16, 2031[152] - The company received $40.0 million upfront from the Revenue Interest Financing Agreement with RTW, obligating it to remit certain revenue interest payments until December 31, 2030[203] Expenses and Cost Management - Cost of revenue decreased by $2.0 million, or 47%, to $2.3 million for the three months ended September 30, 2024, and decreased by $2.6 million, or 26%, to $7.5 million for the nine months ended September 30, 2024, compared to the same periods in 2023[172] - Gross profit decreased by $10.9 million, or 78%, to $3.1 million for the three months ended September 30, 2024, and decreased by $16.1 million, or 46%, to $19.0 million for the nine months ended September 30, 2024, compared to the same periods in 2023[173] - Sales and marketing expenses decreased by $8.8 million, or 63%, to $5.2 million for the three months ended September 30, 2024, and decreased by $18.1 million, or 50%, to $18.0 million for the nine months ended September 30, 2024, compared to the same periods in 2023[174] - Research and development expenses decreased by $4.0 million, or 55%, to $3.2 million for the three months ended September 30, 2024, and decreased by $8.4 million, or 39%, to $13.2 million for the nine months ended September 30, 2024, compared to the same periods in 2023[174] - General and administrative expenses decreased by $11.9 million, or 63%, to $7.0 million for the three months ended September 30, 2024, and decreased by $9.9 million, or 32%, to $20.7 million for the nine months ended September 30, 2024, compared to the same periods in 2023[175] Regulatory and Compliance Issues - The French regulatory authority suspended sales of the Allurion Balloon, prompting the Company to implement a remediation plan[159] - The Company was notified by NYSE that its common stock's average closing price was below $1.00, triggering compliance measures[160] - The Company must obtain stockholder approval for the conversion of notes into common stock, with a proposal due by December 31, 2025[152] Product and Market Development - Allurion completed the enrollment of 550 patients in the AUDACITY clinical trial across 17 sites in the United States, with the last patient treated in September 2024[149] - The Allurion Program includes the world's first swallowable intragastric balloon, which is designed to assist in weight loss without surgery or anesthesia[145] - The Allurion Virtual Care Suite (VCS) provides AI-powered remote patient monitoring tools and a behavior change program, enhancing patient engagement and support[147] - The Allurion VCS was launched in the United States in April 2024 for patients utilizing various weight loss treatments, including anti-obesity medications and bariatric surgery[148] - Allurion's products are currently sold in multiple regions, including Europe, the Middle East, Africa, Latin America, Canada, and the Asia-Pacific region[149] Future Outlook and Strategic Plans - The company expects to continue incurring net losses as it focuses on regulatory approvals, sales strategies, and research and development efforts[150] - The company anticipates needing additional funding for operational expenses, including selling, marketing, and research and development[150] - The company expects to continue generating significant operating losses for the foreseeable future and may need to raise additional capital[184] Stock and Shareholder Information - Allurion's stock began trading on the New York Stock Exchange under the ticker symbol "ALUR" following the completion of its Business Combination on August 2, 2023[151] - The Company raised $15.2 million in net proceeds from a public offering of 14,406,508 shares at an offering price of $1.20 per share[157] - The Company terminated and repaid all outstanding obligations under the Fortress Credit Agreement[155] Risk Factors - The company is exposed to foreign currency risks, particularly in Europe, the Middle East, and the Asia-Pacific region, with a potential 10% adverse change in exchange rates impacting revenues by approximately 6% and net income by about 2%[209] - The company has not engaged in any foreign currency hedging activities to date but will reassess its approach as international operations grow[209] - A hypothetical 10% change in interest rates would not have a material impact on the value of the company's cash, cash equivalents, net loss, or cash flows[209] Accounting and Reporting - The company is classified as an emerging growth company under the JOBS Act, allowing it to delay adopting new accounting standards[208] - The company is also a smaller reporting company, which provides certain exemptions from disclosure requirements, potentially complicating financial comparisons with other public companies[208] - The company may choose to early adopt new accounting standards when permitted for private companies[208] - The fair value of the Revenue Interest Financing Agreement is calculated using a discounted cash flow method based on future revenue projections[203] - The estimated fair value of Legacy Allurion shares was determined by the board of directors, considering various factors including market conditions and financial performance[205]

Financial Data and Key Metrics Changes - Third quarter revenue was $5.4 million, a significant decrease from $18.2 million in the same period of 2023, primarily due to destocking, macroeconomic headwinds, and a product recall in France [35][36] - Gross profit for the third quarter was 58%, down from 77% year-over-year, impacted by the product recall and lower production volumes [36] - Loss from operations decreased to $12.3 million from $26.2 million in the same period last year, driven by reduced operating costs despite lower gross profit [41] Business Line Data and Key Metrics Changes - The AI product revenues grew more than 80% year-over-year, with expectations to double revenues by year-end, driven by expansion in the U.S. and Europe [15][16] - Procedure volumes in the Middle East grew by 20% compared to last year, indicating strength in that region despite challenges in other markets [11] Market Data and Key Metrics Changes - The company noted a recovery in parts of Latin America, which appears to be improving from a macroeconomic standpoint [11] - Approximately 33% of patients now have previously tried an anti-obesity medication, up from 25% last year, indicating a growing market for the Allurion Program [71] Company Strategy and Development Direction - The company announced a new strategy built around five pillars, including a new commercial plan focused on deeper penetration in select markets and scaling the AI product platform [17][18] - The company aims to achieve profitability for the ex-U.S. business by the end of 2025 and resume commercialization in France [18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about resuming commercialization in France and highlighted the potential for the Allurion Balloon as a second-line treatment after GLP-1 discontinuation [30][56] - The management acknowledged macro headwinds but emphasized that the execution of their new plan is within their control [18] Other Important Information - The company has reduced its global headcount by approximately half and consolidated functions under centralized leadership to streamline operations and reduce costs [28] - The last patient exited the AUDACITY trial, with data readout expected at the end of the year, which is crucial for the FDA approval process [29] Q&A Session Summary Question: Can you provide details on the PMA filing and interactions with the FDA? - The first three modules of the PMA have been filed and are under review by the FDA, with positive feedback received so far [48] Question: What is the revenue generation model for the Virtual Care Suite? - The Virtual Care Suite generates revenue on a per patient, per month basis, with both basic and premium versions available for providers [52] Question: Will there be any revenue from the U.S. in 2025? - Some revenue is expected from the Virtual Care Suite in the U.S., but timing for the Allurion Balloon FDA approval remains uncertain [59] Question: Can you quantify the impact from France and destocking in the quarter? - France accounted for over $1 million in revenue, with an additional $1.2 million reduction due to product recall adjustments [66] Question: What is the expected gross margin for Q4 and 2025? - Gross margin is expected to be in the low to mid-60s for Q4, with potential to reach mid-70s by the end of 2025 [60] Question: How are the cost reductions being implemented? - Cost reductions are across all departments, with a focus on maintaining sales effectiveness while reducing marketing expenses [62] Question: What regions showed stronger revenue performance? - The Middle East showed recovery in the balloon business, while Latin America experienced favorable growth due to improved macroeconomic conditions [70]

Revenue Performance - Revenue for Q3 2024 was $5.4 million, down from $18.2 million in Q3 2023, reflecting a year-over-year decrease of approximately 70% due to destocking and sales suspension in France[4]. - Revenue for the three months ended September 30, 2024, was $5,367,000, a decrease of 70.5% compared to $18,200,000 for the same period in 2023[18]. - The company updated its full-year 2024 revenue guidance to between $30 million and $35 million[3]. Profitability and Loss - Gross profit margin for Q3 2024 was 58%, a decrease from 77% in Q3 2023, impacted by product recalls and lower production volumes[5]. - Loss from operations for Q3 2024 was $12.3 million, a decrease of $13.8 million compared to a loss of $26.2 million in Q3 2023[8]. - Net loss attributable to common shareholders for the three months ended September 30, 2024, was $(9,004,000), compared to $(21,885,000) for the same period in 2023[18]. - The company reported a loss from operations of $(12,341,000) for the three months ended September 30, 2024, compared to $(26,154,000) for the same period in 2023[18]. Expenses and Cost Management - Sales and marketing expenses decreased by approximately $8.8 million to $5.2 million in Q3 2024, compared to $14.0 million in Q3 2023, due to increased operational efficiency[6]. - Total operating expenses for the three months ended September 30, 2024, were $15,452,000, a reduction of 61.5% from $40,122,000 in the prior year[18]. - Research and development expenses for the three months ended September 30, 2024, were $3,212,000, a decrease of 55.4% from $7,191,000 in the same period of 2023[18]. - The 2024 Restructuring Plan aims to reduce operating expenses by approximately 50% and achieve profitability by the end of 2025[3]. Cash and Assets - Cash balance as of September 30, 2024, was $28.7 million[9]. - Cash and cash equivalents decreased to $28,654,000 as of September 30, 2024, from $38,037,000 at the end of 2023[19]. - Total assets decreased to $50,699,000 as of September 30, 2024, down from $71,712,000 at the end of 2023[19]. - Total liabilities decreased to $114,510,000 as of September 30, 2024, compared to $142,199,000 at the end of 2023[19]. Clinical Trials and Product Development - AI product revenue from the Virtual Care Suite (VCS) grew by 82% year-over-year, driven by the onboarding of patients treated with GLP-1s in the U.S.[2]. - The last patient in the AUDACITY FDA clinical trial successfully exited, with top-line readout expected by the end of 2024[2]. Shareholder Information - Weighted-average shares outstanding increased to 64,086,265 for the three months ended September 30, 2024, from 40,335,457 in the same period of 2023[18].

Company Overview - Allurion Technologies, Inc. (ALUR) has submitted the first three modules of its premarket approval application (PMA) to the FDA for the Allurion Balloon, utilizing the FDA's modular submission program to enhance application efficiency. The final module, containing clinical data from the AUDACITY trial, is expected to be filed early next year [1] - The Allurion Gastric Balloon is the first swallowable, procedureless gastric balloon designed for weight loss, which can be placed without surgery, endoscopy, or anesthesia, taking approximately 15 minutes during an outpatient visit [2][3] Product Details - The Allurion Balloon helps control appetite by filling space in the stomach and is designed to empty naturally after approximately four months through a time-activated release valve. It is made from polyurethane, ensuring comfort and a snug fit [3] - The AUDACITY trial, a pivotal controlled study involving 550 patients across 17 sites in the U.S., completed enrollment in fall 2023 and is expected to conclude by the end of 2024 [3] Clinical Data and Efficacy - In a study of 121 individuals treated with two consecutive, four-month courses of Allurion balloon therapy, participants lost an average of 22.1% of their body weight after one year, outperforming traditional endoscopic intragastric balloon therapy, which resulted in weight losses of 15.4% and 16.2% [4] - The Allurion Balloon has shown a lower intolerance rate compared to 12-month endoscopic balloons, with a significantly lower overall serious adverse event rate [4][5] Market Potential - The global weight management market was valued at $142.6 billion in 2022 and is projected to grow at a rate of 9.9% from 2023 to 2030, driven by increasing bariatric surgeries, online weight loss program adoption, and rising obesity rates [6] - Allurion's gastric balloon technology is positioned to capitalize on this market growth, potentially boosting the company's business and revenue [6]

Group 1: Penny Stocks Overview - The definition of penny stocks has expanded to include companies trading up to $5 per share, characterized as high-risk, high-reward investments [1] - Penny stocks often consist of newly-established firms or those facing bankruptcy, lacking liquidity and being targets for scams [1] - Despite the risks, penny stocks can offer significant rewards at low costs, attracting investors looking for growth opportunities [1] Group 2: Allurion Technologies - Allurion Technologies (ALUR) is focused on weight loss management, with a program that has shown positive results in a recent systematic review [2] - The weight loss management market is projected to exceed $328 billion by 2032, indicating substantial growth potential [2] - Allurion reported a 25% quarter-over-quarter revenue growth, with analysts giving it a Buy rating and an average price target of $2.88, four times its current price [3] Group 3: Lucid Diagnostics - Lucid Diagnostics (LUCD) provides a test for precancer detection in patients with gastroesophageal reflux disease (GERD), affecting about 20% of the U.S. population [4] - The company experienced a 31% quarter-over-quarter increase in tests performed, with revenue growing fivefold year-over-year [4] - Lucid is positioned to capture a significant share of a U.S. market valued at $25 billion [4] Group 4: KULR Technology Group - KULR Technology Group (KULR) specializes in thermal management solutions for batteries and has secured a $2.4 million contract extension with the U.S. Army [6] - The company is emerging as a leader in sustainable energy management and data center cooling technologies [6] - KULR's technology is increasingly relevant in the growing green energy and data center markets [6] Group 5: Gevo Inc. - Gevo Inc. (GEVO) focuses on renewable fuels, particularly aviation fuel, and has benefited from the Inflation Reduction Act, with shares rising over 48% in the past year [7] - The company produced a record-setting 400,000 British thermal units of renewable natural gas (RNG) in the latest quarter [7] - Analysts have set an average price target of $5.68 for Gevo, indicating significant upside potential from its current trading price [7]

Financial Performance - Allurion generated revenue of $21.2 million for the six months ended June 30, 2024, compared to $27.0 million for the same period in 2023, reflecting a decrease of approximately 21%[159]. - The company incurred a net loss of $39.8 million for the six months ended June 30, 2023, while achieving a net income of $3.4 million for the same period in 2024[159]. - Revenue decreased by $1.2 million, or 9%, to $11.8 million for the three months ended June 30, 2024, and decreased by $5.8 million, or 22%, to $21.2 million for the six months ended June 30, 2024, compared to the same periods in 2023[185]. - Gross profit decreased by $1.0 million, or 10%, to $9.0 million for the three months ended June 30, 2024, and decreased by $5.2 million, or 25%, to $15.9 million for the six months ended June 30, 2024[187]. - The company recorded a loss of $8.7 million on extinguishment of debt for both the three and six months ended June 30, 2024[195]. - As of June 30, 2024, the company had $19.3 million in cash and cash equivalents, with an accumulated deficit of $209.4 million[198]. - Cash outflows from operating activities were $17.6 million for the six months ended June 30, 2024, compared to $20.0 million for the same period in 2023[198]. - The company has substantial doubt about its ability to continue as a going concern for a period of one year from the date of the financial statements due to recurring losses and the need for additional capital[199]. Product Development and Market Presence - Allurion completed the enrollment of 550 patients in the AUDACITY clinical trial across 17 sites in the United States during the third quarter of 2023[158]. - The Allurion VCS was launched in the United States in April 2024 for patients utilizing various weight loss treatments, including anti-obesity medications and bariatric surgery[157]. - The Allurion Program includes the world's first swallowable, procedure-less intragastric balloon for weight loss, along with AI-powered remote patient monitoring tools[155]. - The Allurion App integrates data from the Allurion Connected Scale to monitor various health metrics and is available in 15 languages[156]. - Allurion's products are currently sold in multiple regions, including Europe, the Middle East, Africa, Latin America, Canada, and the Asia-Pacific region[158]. - The company aims to increase market acceptance of its products to drive sales growth and expand its customer base in existing and new markets[171]. - Regulatory approval and timely introduction of new products are critical for the company's sales growth and market presence[172]. Financial Agreements and Capital Structure - The company issued $48 million in convertible senior secured notes with an annual interest rate of 6.0%, maturing on April 16, 2031[163]. - The company has increased the revenue interest payments to be paid to RTW from 6% to 12% for net sales less than or equal to $100 million prior to December 31, 2026[164]. - The public offering on June 28, 2024, resulted in gross proceeds of $17.3 million from the sale of 14,406,508 shares at an offering price of $1.20 per share[167]. - A private placement on June 28, 2024, generated approximately $2.7 million from the sale of 2,260,159 shares of Series A Preferred Stock and accompanying warrants[168]. - The company received $48 million in gross proceeds from the Amended Note Purchase Agreement with RTW on April 16, 2024, which was used to repay the Fortress Term Loan[205]. - The Revenue Interest Financing Agreement with RTW provided $40 million in proceeds, with an increased revenue interest payment rate from 6% to 12% for net sales less than or equal to $100 million prior to December 31, 2026[206]. Operational Expenses - Operating expenses include sales and marketing, research and development, and general and administrative costs, impacting overall financial performance[176][177]. - Sales and marketing expenses decreased by $3.6 million, or 35%, to $6.7 million for the three months ended June 30, 2024, and decreased by $9.3 million, or 42%, to $12.8 million for the six months ended June 30, 2024[188]. - Research and development expenses decreased by $2.3 million, or 35%, to $4.3 million for the three months ended June 30, 2024, and decreased by $4.4 million, or 30%, to $10.0 million for the six months ended June 30, 2024[189]. - General and administrative expenses increased by $0.9 million, or 14%, to $7.3 million for the three months ended June 30, 2024, and increased by $2.0 million, or 17%, to $13.7 million for the six months ended June 30, 2024[190][191]. - Interest expense decreased by $2.2 million, or 86%, to $0.3 million for the three months ended June 30, 2024, and decreased by $2.5 million, or 52%, to $2.3 million for the six months ended June 30, 2024[192]. Regulatory and Compliance Issues - The French regulatory authority suspended sales of the Allurion Balloon, prompting the company to withdraw the device from the French market pending a remediation plan[169]. - The company received a letter from NYSE regarding non-compliance with the minimum share price requirement, with an average closing price below $1.00 for 30 consecutive business days[170]. - The company is classified as an emerging growth company, allowing it to delay adopting new accounting standards[221]. Cash Flow and Investments - Net cash used in investing activities was $0.5 million for the six months ended June 30, 2024, primarily for purchases of property and equipment[212]. - Cash used in financing activities was $0.7 million for the six months ended June 30, 2024, including a $47.7 million repayment of the Fortress Term Loan[213]. - As of June 30, 2024, the company had cash and cash equivalents totaling $19.3 million, primarily invested in money market funds[222]. - A hypothetical 10% change in interest rates would not have a material impact on the value of cash, cash equivalents, net loss, or cash flows[222]. - A 10% adverse change in foreign exchange rates could impact revenues by approximately 7% and net income by approximately 6%[222].

Financial Data and Key Metrics Changes - Revenue for Q2 2024 was $11.8 million, a sequential increase of $2.4 million or 25% from Q1 2024, but a decrease of $1.2 million from Q2 2023 [6][22] - Gross profit was 76% compared to 77% for the same period a year ago [23] - Loss from operations decreased by $3.9 million or 30% to $9.3 million compared to $13.3 million in the same period in 2023 [24] Business Line Data and Key Metrics Changes - Procedure volume grew by 12% compared to the same period in 2023, equating to over 10,000 Allurion balloon placements for two consecutive quarters [7] - Operating expenses and loss from operations reduced by 21% and 30% respectively compared to the prior year period [9] Market Data and Key Metrics Changes - France represents approximately 15% of the company's business over the past two quarters, with macroeconomic headwinds in Latin America and Asia Pacific leading to slower procedure growth [12] - The company adjusted its full-year procedure volume growth forecast to between 10% and 15% and expects full-year revenue to range between $40 million and $45 million [12] Company Strategy and Development Direction - The company aims to achieve profitability by the end of 2025, focusing on operational efficiencies and cost reduction initiatives [9][10] - Allurion is exploring partnerships with pharmacies and providers to offer its products to patients who have not found success with GLP-1 drugs [14] - The company is advancing its digital platform, including the Allurion Virtual Care Suite, to enhance patient monitoring and support [16] Management's Comments on Operating Environment and Future Outlook - Management noted that the French regulatory authority's actions were not based on new scientific evidence and emphasized ongoing cooperation to resume commercialization in France [11][27] - The company is optimistic about achieving top-line revenue growth next year, despite current challenges [36] Other Important Information - The company raised $22 million in gross proceeds through a public offering and a concurrent private placement of securities [10] - A new Chief Operating Officer, Ojas A. Buch, has been appointed to strengthen the management team [21] Q&A Session Summary Question: What prompted the action by the French regulatory authority? - The French regulatory authority focused on advertising, follow-up programs, and training related to the balloon, but the decision was not based on new scientific evidence [27] Question: How much of the path to profitability is based on lowering operating expenses? - Expense management and extracting efficiencies will be significant contributors to the path to profitability [30] Question: Can you quantify the impact of France inventory and macro headwinds on guidance reduction? - France accounts for approximately 15% of business, and macro headwinds have led to reduced anticipated procedural volume and conservative inventory restocking [34] Question: Will France contribute to revenue next year? - The hope is that France will contribute to revenue next year, and some macro headwinds are expected to improve [36] Question: Are there learnings from France that can be applied to other markets? - There are some learnings that may be incorporated into marketing and follow-up strategies in other parts of Europe, but the issue is largely isolated to France [38]

Financial Performance - Second quarter revenue reached $11.8 million, a sequential increase of $2.4 million or 25% from Q1 2024[2] - Revenue for Q2 2024 was $11,766,000, a decrease of 9.2% compared to $12,960,000 in Q2 2023[20] - Gross profit for Q2 was 76%, slightly down from 77% in the same period last year[8] - Gross profit for Q2 2024 was $8,993,000, down from $9,968,000 in Q2 2023, representing a decline of 9.8%[20] - Net loss for Q2 2024 was $2,162,000, compared to a net loss of $21,996,000 in Q2 2023, showing significant improvement[20] - The company reported a basic net income (loss) per share of $(0.05) for Q2 2024, compared to $(0.84) for Q2 2023[20] Expenses and Cost Management - Loss from operations decreased by 30% year-over-year, amounting to $9.3 million compared to $13.3 million in Q2 2023[11] - Sales and marketing expenses decreased by approximately $3.6 million to $6.7 million compared to $10.3 million in Q2 2023[8] - Research and development expenses decreased by $2.3 million to $4.3 million, driven by reduced costs related to the AUDACITY clinical trial[9] - Total operating expenses for Q2 2024 were $18,339,000, a decrease of 21.3% from $23,262,000 in Q2 2023[20] - Research and development expenses for Q2 2024 were $4,310,000, down from $6,581,000 in Q2 2023, a reduction of 34.5%[20] Cash and Assets - Cash balance as of June 30, 2024, was $19.3 million, prior to the closing of a public offering generating approximately $22 million in gross proceeds[12] - Cash and cash equivalents decreased to $19,258,000 as of June 30, 2024, down from $38,037,000 at the end of 2023[21] - Total assets decreased to $46,550,000 as of June 30, 2024, from $71,712,000 at the end of 2023[21] - Total liabilities decreased to $117,132,000 as of June 30, 2024, down from $142,199,000 at the end of 2023[21] Operational Highlights - Procedure volume grew by 12% year-over-year, resulting in over 10,000 Allurion balloon placements for the second consecutive quarter[2] - Full-year 2024 revenue guidance updated to between $40 million and $45 million, with expected growth in procedure volume between 10% and 15%[5] - The Company is implementing a remediation plan in response to the suspension of sales of the Allurion Balloon in France[4] - The launch of GLP-1 drug support for Coach Iris aims to enhance patient outcomes in weight loss management[3]